Cargando…
Topical rapamycin (sirolimus) for facial angiofibromas
Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at...
Autor principal: | Madke, Bhushan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573457/ https://www.ncbi.nlm.nih.gov/pubmed/23439391 http://dx.doi.org/10.4103/2229-5178.105488 |
Ejemplares similares
-
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017) -
Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015) -
Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type
por: Viswanath, Vishalakshi, et al.
Publicado: (2016) -
Ingenol mebutate: A novel topical drug for actinic keratosis
por: Aditya, Suruchi, et al.
Publicado: (2013) -
Topical Ciclopirox Olamine 1%: Revisiting a Unique Antifungal
por: Sonthalia, Sidharth, et al.
Publicado: (2019)